Theralase Technologies Inc. V.TLT

Finance question

[DJDawg]

Hello all,
Congrats on a pretty great day. Since we are in the usual limbo between updates, I had a question about finances:
- I get that the monthly burn is not too bad so we are good to go for the NMIBC trial for now.
- I understand that when the warrants are excercised that that will give the company some more cash. Great.

What I didn't quite understand
- Why did they withdraw the shelf offering option in mid Nov. I'm glad they did as it show confidence but at the same time. Having that in your back pocket makes sense to any company. Why take it away?
- People expected the most recent warrants in Nov to be extended from what I read. But they were not. Isn't extending the warrants a good way to get more cash in the future. So why not do it from the company's perspective.

Maybe the answer is obvious but explain it to my life I'm 5. :)

[Longholder99]

I think this was answered already. Im thinking that maybe they just dont need the money. Just my opinion.

[skys1]

DJDawg, the answer to your question is quite simple. They didn't renew the warrants and withdrew the Shelf was because they know they now have a funding source they didn't have before. My guess it's St Mikes/Unity Health, but keep in mind they have enough cash to get them through Ph 2, so it could be a while before we find out unless they file a new indication, which is a strong

[StevenBirch]

Skys, they always said they would commence Phase 1b trials on GBM and NSCLC when Phase II "was well underway". That is a subjective phrase but it could be when they receive BTD which could be very near. Then as you say that's when St. Mikes/Unity may come into play and who knows maybe they already have a deal based on getting that approval - which of course wouldn't be released

[skys1]

Steven, I agree all those items must be fairly close and we should see them in 2022. It should really light a fire under TLT if it still exists in its current corporaste structure, or whoever owns rights.

[Oilminerdeluxe]

Could BTD be that close? Wouldn't mind it at all. 

[Galaxym31]

What is BTD ?

[Jaro1977]

breakthrough therapy designation https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy

[Jaro1977]

also Buy.The.Dip

[Yajne]

Thanks Jaro for posting the link. I have always wondered if BTD on NIMBC indication could benefit other indications that will utilize the same drug, not that the BTD will cover the next indication, but rather that the new indication might be on 'FDA radar' at an earlier stage and therefore that 'intensive guidance' might allow it to move to FT status earlier, maybe even upon a

[Rumpl3StiltSkin]

Well those warrants expiring means the float is now ~275Million shares. So that is good.  As far as why they pulled the shelf offering? Well they can always re-do it. Or for some reason they feel they don't need it, that probably means something great. :-)

[NgamiaSwede]

Rumpl3 I have seen this before, in that time the shelf was pulled to make a partner more willing to grab. When you want a bite you do not want the bite to be smaller after a while because new shares come in play Best Regards Mikael

[NgamiaSwede]

Could be that someone is trying to get shares on the market and get a go from Theralase, Theralase know this means warrants will strike. They get a partner they want, money in the bank. Share go upp and all are happy. The partner get a shunk to make there mark to other dragon to keep away. We are in 2 CAD in 2 month time in that case Best Regards

[Rumpl3StiltSkin]

Ah, yes Swede. That does make sense, could also explain letting the 37.5c warrants expire instead of extendig them. Smaller float to sweeten the deal!